Serum Biomarkers and Gene Polymorphisms in COPD and COPD with T2DM Patients
Springer Science and Business Media LLC - Trang 1-10 - 2024
Tóm tắt
Inflammation plays an important role in chronic obstructive pulmonary disease (COPD). Increasing evidence points to the role of inflammation in the pathogenesis of type 2 diabetes mellitus (T2DM). We investigated the adiponectin: leptin and IL-8 genes in COPD-induced T2DM patients, along with the effect of polymorphism on the levels of these cytokines. We enrolled COPD, COPD plus T2DM, and healthy subjects from the institution according to standard criteria. Further, we drew a blood sample and performed genotypic analysis and an enzyme-linked immunosorbent assay (ELISA). We enrolled a total of 500 subjects in this study, including 250 controls, 191 COPD patients, and 59 COPD patients with T2DM. Genotyping of leptin (C/T), adiponectin (C/G), and IL-8 (C/T) polymorphisms was performed. Serum levels of leptin, adiponectin, and IL-8 were significantly higher (P < 0.001) in COPD with diabetes when compared with COPD in healthy individuals. The genotype frequency of the “CT” leptin gene variant was significantly associated with the risk of developing COPD by 3.7 folds, although it was not associated with the development of T2DM in COPD. Whereas genotype ‘TT’ was significantly associated with the risk of developing T2DM in COPD patients by 2.4 folds. It indicates that individuals with genotype ‘TT’ are at higher risk of developing COPD, and moreover, they are at higher risk of developing T2DM. We conclude that genotypes ‘TT’ of leptin, ‘GG’ diponectin, and ‘TT’ of IL-8 may be exploited as biomarkers for the prognosis and diagnosis of T2DM in COPD and COPD, respectively. While ‘CT’ of IL-8 was a protective biomarker against COPD.
Tài liệu tham khảo
Verma AK, Pandey AK, Singh A, Kant S, Mahdi AA, Prakash V, et al. Increased serum levels of Matrix-metalloproteinase-9, Cyclo-oxygenase-2 and prostaglandin E-2 in patients with Chronic Obstructive Pulmonary Disease (COPD). Indian J Clin Biochem. 2022;37(2):169–77.
Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956–62.
Laghi F, Adiguzel N, Tobin MJ. Endocrinological derangements in COPD. Eur Respir J. 2009;34(4):975–96.
Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of Diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–9.
Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–50.
Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of Chronic Obstructive Pulmonary Disease. Cochrane Database Syst Rev. 2014;9:CD001288.
Franssen FM, O’Donnell DE, Goossens GH, Blaak EE, Schols AM. Obesity and the lung: obesity and COPD. Thorax. 2008;63(12):1110–7.
Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE, Colditz GA, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care. 2004;27(10):2478–84.
Mahishale V, Mahishale A, Patil B, Sindhuri A, Eti A. Screening for diabetes mellitus in patients with chronic obstructive pulmonary disease in tertiary care hospital in India. Nigerian Med J. 2015;56(2):122–5.
Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370(9589):797–9.
Rothnie KJ, Chandan JS, Goss HG, Müllerová H, Quint JK. Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care. Int J Chronic Obstr Pulm Dis. 2017;12:1663–8.
Rasmussen SM, Brok J, Backer V, Thomsen SF, Meteran H. Association between chronic obstructive pulmonary disease and type 2 diabetes: a systematic review and meta-analysis. COPD. 2018;15(5):526–35.
Mohamed NA, Fawzy MA, Elgamry R, Gad DM, Ibraheem HA. Role of adiponectin and other inflammatory biomarkers in COPD patients Egypt J Chest Dis Tuberculosis. 2013;62:45–50.
Ho TW, Huang CT, Ruan SY, Tsai YJ, Lai F, Yu CJ. Diabetes mellitus in patients with chronic obstructive pulmonary disease-the impact on mortality. PLoS ONE. 2017;12(4):e0175794.
Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respir Int Rev Thorac Dis. 2010;80(2):89–95.
Teijeira A, Garasa S, Ochoa MDC, Cirella A, Olivera I, Glez-Vaz J, et al. Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils. Eur J Immunol. 2021;51(9):2274–80.
O’Byrne PM, Rennard S, Gerstein H, Radner F, Peterson S, Lindberg B, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med. 2012;106(11):1487–93.
Nocker RE, Schoonbrood DF, van de Graaf EA, Hack CE, Lutter R, Jansen HM, et al. Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol. 1996;109(2):183–91.
Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–36.
Lin CS, Liu CC, Yeh CC, Chang YC, Chung CL, Lane HL, et al. Diabetes risks and outcomes in Chronic Obstructive Pulmonary Disease patients: two nationwide population-based retrospective cohort studies. PLoS ONE. 2017;12(8):e0181815.
Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodríguez LA, Ruigómez A, Meier CR, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(5):686–9.
García Rodríguez LA, Pérez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45(5):419–25.
Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14.